ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
11 nov. 2019 03h21 HE
|
ASLAN PHARMACEUTICALS LIMITED
- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
31 oct. 2019 03h37 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
18 oct. 2019 03h35 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3...
New Data Presented on ASLAN’s varlitinib at ESMO 2019
02 oct. 2019 02h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...
ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO
19 sept. 2019 03h50 HE
|
ASLAN PHARMACEUTICALS LIMITED
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...
Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019
10 sept. 2019 05h14 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting
27 août 2019 06h00 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13 août 2019 04h03 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer
10 mai 2019 04h15 HE
|
ASLAN Pharmaceuticals Limited
- K-MASTER, Korea’s leading precision medicine research group, to conduct phase 1b/2 umbrella study testing varlitinib as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic...
ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
26 févr. 2019 17h35 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...